Also known as: Aethlon Medical
Aethlon Medical is a medical therapeutics company developing immunotherapeutic devices for cancer and viral infections. Its lead program is the Hemopurifier, a clinical-stage device for oncology and severe viral disease applications.
Agentic AI models are streamlining oncology clinical trial design and reducing phase II to III failure risk. Separately, Aethlon Medical progresses its Hemopurifier device trial in Australia with strong safety data and accelerated patient recruitment.
Aethlon Medical reported Q3 2026 financial results with a $2.06 million operating loss while advancing its Australian oncology trial of the Hemopurifier device. The company achieved 27% year-to-date cost reductions and targets a late March safety review.
